Related Experiment Video
Updated: May 14, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Sex Hormone-Binding Globulin and Cardiac Function in Men with Heart Failure: Possible Role of Diabetes
Viktor Čulić1,2, Željko Bušić3, Riccardo Vio4
1Department of Cardiology and Angiology, University Hospital Centre Split, Šoltanska 1, 21000 Split, Croatia.
Insights
In men with heart failure (HF) and type 2 diabetes mellitus (T2DM), higher sex hormone-binding globulin (SHBG) is linked to worse heart function. Testosterone, however, shows a protective effect in these patients.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Disorders
Background:
- The relationship between sex hormone-binding globulin (SHBG) and heart failure (HF) is debated, especially in patients with type 2 diabetes mellitus (T2DM).
- Understanding these associations is crucial for managing cardiovascular health in diabetic populations.
Purpose of the Study:
- To investigate the association between SHBG levels and clinical/echocardiographic parameters of HF in men.
- To differentiate these associations based on the presence or absence of T2DM.
Main Methods:
- Prospective collection of data from 215 male patients hospitalized for acute HF.
- Assessment included baseline characteristics, risk factors, medications, serum SHBG, total testosterone, and echocardiographic parameters.
- Multivariate analysis was used to determine independent associations.
Main Results:
- Patients with T2DM exhibited older age, higher BMI, and more severe HF symptoms (NYHA class).
- A significant correlation between SHBG and left ventricular ejection fraction (LVEF) was found only in T2DM patients (r = 0.456).
- Increased SHBG independently predicted lower LVEF in T2DM patients (ß = -0.542), while higher testosterone predicted higher LVEF (ß = 0.531).
Conclusions:
- In men with HF and T2DM, SHBG demonstrates an independent adverse impact on LVEF, explaining 12.5% of its variance.
- Conversely, testosterone appears to have a beneficial role in preserving LVEF in this cohort.
- Further research into the subcellular mechanisms of SHBG in diabetic heart disease is warranted.
Abstract:
Background: The association of sex hormone-binding globulin (SHBG) with heart failure (HF) remains a topic of ongoing debate, particularly in the light of type 2 diabetes mellitus (T2DM). We aimed to assess the association of SHBG with clinical and echocardiographic parameters of HF in men according to the presence of T2DM. Methods: Data on baseline characteristics, cardiovascular risk factors and medications, laboratory findings including serum SHBG and total testosterone concentrations, and echocardiographic parameters were prospectively collected for 215 male patients consecutively hospitalized for an acute episode of HF. Results: Patients with T2DM were older (p = 0.013), had a greater body mass index (p = 0.009) and NYHA class (p = 0.001), and were more likely to have hypertension (p < 0.001) or hyperlipidemia (p = 0.032). A moderate correlation among SHBG and total testosterone with the left ventricular ejection fraction (LVEF) was observed only in T2DM patients (r = 0.456) but not among non-T2DM patients (r = 0.194). A multivariate analysis revealed the independent association of increased SHBG levels with lower LVEF values among T2DM patients (ß = -0.542, p < 0.0001), whereas in the same group higher total testosterone was an independent predictor of higher LVEF (ß = 0.531, p < 0.0001) and lower LVDD (ß = -0.442, p = 0.0002) levels. Conclusions: In men with HF and T2DM, in contrast to testosterone, SHBG may have an independent adverse impact on the LVEF, which may account for 12.5% of the variance in LVEF levels. The possible subcellular mechanisms of SHBG in men with diabetic myocardial disorder should be additionally explored.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Pathophysiology of Heart Failure
Hormonal Regulation
Heart Failure Drugs: Inotropic Agents

